CAJ | 학술논문

目的：探讨阿托伐他汀在缺血性脑卒中治疗中对氧化应激和脂质过氧化的影响。方法将2012年6月至2013年9月收治的96例缺血性脑卒患者随机分为观察组和对照组各48例，对照组仅给予对症支持治疗，观察组在对照组基础上加用阿托伐他汀治疗，比较两组患者治疗效果及血浆8-异前列腺素F2α（8-iso-PGF2α）和氧化低密度脂蛋白（ox-LDL）水平。结果两组患者入院时收缩压（SBP）、舒张压（DBP）、体质量指数（BMI）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、8-iso-PGF2α及ox-LDL比较，差异均无统计学意义（P＞0.05），经过治疗后，观察组8-iso-PGF2α及ox-LDL两项指标较治疗前无明显变化（P＞0.05），而对照组则较治疗前明显增高，差异有统计学意义（P＜0.01）；同时，在临床疗效方面，观察组总有效率为95.8%（46/48），治愈率为12.5%（6/48），均显著高于对照组[70.8%（34/48）和2.1%（1/48）]，差异有统计学意义（P＜0.05）。结论阿托伐他汀能有效对抗氧化应激与脂质过氧化反应，改善缺血性脑卒中患者临床症状和体征，有效促进神经功能的恢复，提高患者生活质量。
목적：탐토아탁벌타정재결혈성뇌졸중치료중대양화응격화지질과양화적영향。방법장2012년6월지2013년9월수치적96례결혈성뇌졸환자수궤분위관찰조화대조조각48례，대조조부급여대증지지치료，관찰조재대조조기출상가용아탁벌타정치료，비교량조환자치료효과급혈장8-이전렬선소F2α（8-iso-PGF2α）화양화저밀도지단백（ox-LDL）수평。결과량조환자입원시수축압（SBP）、서장압（DBP）、체질량지수（BMI）、삼선감유（TG）、총담고순（TC）、저밀도지단백담고순（LDL-C）、고밀도지단백담고순（HDL-C）、8-iso-PGF2α급ox-LDL비교，차이균무통계학의의（P＞0.05），경과치료후，관찰조8-iso-PGF2α급ox-LDL량항지표교치료전무명현변화（P＞0.05），이대조조칙교치료전명현증고，차이유통계학의의（P＜0.01）；동시，재림상료효방면，관찰조총유효솔위95.8%（46/48），치유솔위12.5%（6/48），균현저고우대조조[70.8%（34/48）화2.1%（1/48）]，차이유통계학의의（P＜0.05）。결론아탁벌타정능유효대항양화응격여지질과양화반응，개선결혈성뇌졸중환자림상증상화체정，유효촉진신경공능적회복，제고환자생활질량。
Objective To discuss the influence of atorvastatin on oxidative stress and lipid peroxidation in patients with cerebral ischemic stroke(CIS). Methods Totally 96 patients with CIS were randomly divided into observation group and control group,48 cases in each group. The control group were given conventional therapy , and the observation group were added with a-torvastatin based on the control group,then the clinical effects,plasma 8-isoprostanes F2α(8-iso-PGF2α) and oxidized low-denisty lipoprotein (ox-LDL) were contrasted between the two groups. Results There was no significantly difference in systolic blood pressure (SBP),diastolic blood pressure (DBP),body mass index (BMI),triacylglycerol (TG),total cholesterol (TC),low density lipoprotein cholesterin(LDL-C),high density lipoprotein cholesterin(HDL-C),8-iso-PGF2α,and ox-LDL between the two groups before treatment(P>0.05). After treatment,there was no significantly difference in 8-iso-PGF2αand ox-LDL in the observation group(P>0.05),but significantly elevated in the control group(P<0.01);the effective rate was 95.8%(46/48),and the cure rate 12.5%(6/48) in the observation group,which were significantly higher than 70.8%(34/48) and 2.1%(1/48) in the control group (P<0.05). Conclusion Atorvastatin can effectively against oxidative stress and lipid peroxidation ,improve clinical signs and symptoms in patients with CIS,effectively promote the recovery of neurological function and improve quality of life in the patients.